{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.70","value":"1.7"},{"groupId":"OG001","spread":"20.99","value":"2.7"}]}],"title":"Global Health Status / QoL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.32","value":"0.1"},{"groupId":"OG001","spread":"18.30","value":"4.4"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.59","value":"-1.9"},{"groupId":"OG001","spread":"26.92","value":"-2.6"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.17","value":"2.5"},{"groupId":"OG001","spread":"18.32","value":"3.4"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.79","value":"2.0"},{"groupId":"OG001","spread":"20.75","value":"0.2"}]}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.64","value":"-2.9"},{"groupId":"OG001","spread":"24.09","value":"-0.9"}]}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.84","value":"-1.9"},{"groupId":"OG001","spread":"23.77","value":"-9.0"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.34","value":"2.1"},{"groupId":"OG001","spread":"13.11","value":"-1.2"}]}],"title":"Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.40","value":"-2.1"},{"groupId":"OG001","spread":"21.77","value":"-1.7"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.34","value":"-1.6"},{"groupId":"OG001","spread":"26.59","value":"-8.8"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.30","value":"-4.0"},{"groupId":"OG001","spread":"33.95","value":"-3.0"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.55","value":"-1.1"},{"groupId":"OG001","spread":"25.14","value":"-0.0"}]}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.36","value":"-0.8"},{"groupId":"OG001","spread":"23.23","value":"0.9"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.58","value":"1.6"},{"groupId":"OG001","spread":"18.58","value":"1.2"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.15","value":"-0.8"},{"groupId":"OG001","spread":"22.75","value":"-1.5"}]}],"title":"Financial difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 is composed of 30 items that includes a global health status score ranging from: 1-7 as well as scores for 5 functional scales (physical, role, emotional, cognitive and social), 3 symptom scales (fatigue, nausea/vomiting, and pain) and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) all ranging from 1-4. Subscale scores are transformed to a 0 to 100 scale. A high score for a functional scale represents a high or healthy level of functioning; a high score for the global health status/health related quality of life (HRQoL) represents a high overall HRQoL; but a high score for a symptom scale represents a high level of symptomatology or problems. Baseline is defined as the last value on or before the first dose of study drug.","dispersionType":"Standard Deviation","groups":[{"description":"Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg.","id":"OG000","title":"Luspatercept"},{"description":"Starting dose of 450 IU/kg (maximum total starting dose is 40,000 IU) subcutaneous injection once every week (7 days; QW). Dose levels can be increased in a stepwise manner beyond the starting dose to 787.5 IU/kg, and up to a maximum of 1,050 IU/kg (with a maximum total dose of 80,000 IU).","id":"OG001","title":"Epoetin Alfa"}],"paramType":"MEAN","populationDescription":"All randomized participants who completed the EORTC QLQ-C30 assessment at baseline and post-baseline assessment at the respective visit.","reportingStatus":"POSTED","timeFrame":"Baseline and week 24.","title":"Change From Baseline in the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}